Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patients compared to their tumor mutation burden by Danielle Medeiros | Nov 12, 2019 | 0 comments Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment Name * Email * Website Currently you have JavaScript disabled. In order to post comments, please make sure JavaScript and Cookies are enabled, and reload the page. Click here for instructions on how to enable JavaScript in your browser.
